サイトメトリーリサーチ
Online ISSN : 2424-0664
Print ISSN : 0916-6920
ISSN-L : 2424-0664
総説
骨髄異形成症候群のFlow Cytometry 解析:現在と未来
緒方 清行山元 由美
著者情報
ジャーナル フリー

2022 年 32 巻 1 号 p. 1-7

詳細
抄録

Myelodysplastic syndromes (MDS) are malignant disorders of hematopoietic cells and show cytopenia and myeloid dysplasia. Since many low-grade MDS patients lack objective abnormalities (such as blast excess, typical cytogenetic abnormalities, and ringed sideroblasts), the diagnosis of these patients is often problematic. Diagnostic process of these patients includes confi rmation of dysplastic myeloid cells by a microscope and ruling out other diseases causing cytopenia, which requires considerable experience and a great deal of knowledge. Flow cytometry (FCM) has been proposed as an adjunctive diagnostic tool for low-grade MDS patients in the World Health Organization classifi cation.

Since the bone marrow of low-grade MDS is heterogeneous, design of analysis protocol is vitally important. For this purpose, our group proposed a simple FCM protocol (so-called Ogata score), which analyzes four quantitative FCM parameters. The reproducibility and clinical utility of this protocol for diagnosing low-grade MDS have been validated in many studies including a large European LeukemiaNet study. Furthermore, many researchers are working to increase the sensitivity of the Ogata score. Regarding high-grade MDS, azacitidine (AZA) is the only drug proven to prolong survival in these patients. However, the response rate to AZA is only 40-50% and, even if patients respond, it is mostly transient. No strong prognostic markers in AZA-treated patients have been recognized. Our group analyzed

115 patients treated with AZA and found that patients whose blasts express CD41, a megakaryocyte/platelet lineage marker, showed poorer survival compared with other patients. FCM is useful in diagnosis and prognostication of MDS.

著者関連情報
© 2022 日本サイトメトリー学会
次の記事
feedback
Top